Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP208752.RAB6SpkB84-qmOSk9kT2pmWHOWvQU-gjARw83fb9kfXoE130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP208752.RAB6SpkB84-qmOSk9kT2pmWHOWvQU-gjARw83fb9kfXoE130_provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP354000.RATKoJ2JSN3vXPcCdULdnWzv4_vHcISnrzMvWDm-Sj7gM130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP354000.RATKoJ2JSN3vXPcCdULdnWzv4_vHcISnrzMvWDm-Sj7gM130_provenance.
• NP907487.RAq9mi5PX01SBs90r5WLueRUtDb7mE7cnqH4v_aZkV-dA130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP907487.RAq9mi5PX01SBs90r5WLueRUtDb7mE7cnqH4v_aZkV-dA130_provenance.
• NP315651.RAYV9Yy3S_mMH-ygH6JXOntbzhu7AK3CW42GlJsb-WR2o130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP315651.RAYV9Yy3S_mMH-ygH6JXOntbzhu7AK3CW42GlJsb-WR2o130_provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP466641.RA38cAD_Q5xTBPkqdI6-7NIWUGYj0qRcLA0AcB7YYdw1k130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP466641.RA38cAD_Q5xTBPkqdI6-7NIWUGYj0qRcLA0AcB7YYdw1k130_provenance.
• NP468111.RAsLfo9XXGQtcqvelHpHlznEjDlfKwvMikc60k29hM6pE130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468111.RAsLfo9XXGQtcqvelHpHlznEjDlfKwvMikc60k29hM6pE130_provenance.
• NP613315.RAnZeMkxTfa5PxqbGqDQUvTyUaNMoaVrrFUXKtX2GWDmU130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613315.RAnZeMkxTfa5PxqbGqDQUvTyUaNMoaVrrFUXKtX2GWDmU130_provenance.
• NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP674860.RA5wLYo0vvHfE9D0iRTgc99H66QK6GzCkU7dc-GBDxRcY130_provenance.
• NP427384.RAWcqdczRkaAXA3MbO2yXfwm88-mqLuI0lIFJVUrn-PiM130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427384.RAWcqdczRkaAXA3MbO2yXfwm88-mqLuI0lIFJVUrn-PiM130_provenance.
• NP628502.RAIBHvv7gRHSH2Nwb2BRQrvg2j35pja1-D0LaxegdiAu4130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628502.RAIBHvv7gRHSH2Nwb2BRQrvg2j35pja1-D0LaxegdiAu4130_provenance.
• NP480215.RAQtNBQg0-BiBjW2B459rgfRyIZuYdTZJ1IOvONzLz9t0130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480215.RAQtNBQg0-BiBjW2B459rgfRyIZuYdTZJ1IOvONzLz9t0130_provenance.
• NP480214.RAiDcW4hg4plnpeOkwT10nl3hapIPNWiKqgKZNJIW61IU130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480214.RAiDcW4hg4plnpeOkwT10nl3hapIPNWiKqgKZNJIW61IU130_provenance.
• NP857543.RAFV5hGHnhW-Mozraw1Qls45qiTaWY6adUJsR1xEFmh1U130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP857543.RAFV5hGHnhW-Mozraw1Qls45qiTaWY6adUJsR1xEFmh1U130_provenance.
• NP427143.RA00LhZmx6i3fBFgt_V6rueSZ-tD8a9XC7s8laROmSu-4130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427143.RA00LhZmx6i3fBFgt_V6rueSZ-tD8a9XC7s8laROmSu-4130_provenance.
• NP427510.RAxy-gNuGfUQs79DTNyYJWrsX5yTZb4XQgyVljVubJzLc130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427510.RAxy-gNuGfUQs79DTNyYJWrsX5yTZb4XQgyVljVubJzLc130_provenance.
• NP480216.RA4IXDJ6nWZZnpZStu-XYcrzdgsQZwCH3j_rlEY4zPPiU130_assertion description "[In vitro assessment of targeting by the CNGRC/PEG/PEI/DNA vector carrying a beta-galactosidase (beta-Gal)-expressing plasmid showed as much as a 5-fold increase in transduction, relative to the untargeted PEG/PEI/DNA-betagal vector, of CD13-positive lung cancer, fibrosarcoma, bladder cancer, and human umbilical vein endothelial cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480216.RA4IXDJ6nWZZnpZStu-XYcrzdgsQZwCH3j_rlEY4zPPiU130_provenance.